Introduction
============

Hyperglycemia, defined as serum glucose \> 11 mmol/l after subarachnoid hemorrhage, is a common finding and is an independent predictor of long term poor outcome \[[@B1],[@B2]\]. It is believed that the surge in serum glucose immediately after injury is related to a complex interrelationship between sympathetic and inflammatory mediators, acquired insulin resistance and administration of dexamethasone \[[@B3]\].

While such observational data argue for tight glycemic control, recent studies investigating the relationship between serum and brain glucose levels have found that intensive insulin protocols targeted to a tight serum glucose level (4.4 to 6.1 mmol/l) may compromise cerebral metabolism by leading to concomitant critical reductions in interstitial brain glucose levels \[[@B4],[@B5]\].

Each of these studies did not take into account the impact that nutritional support may have upon outcomes related to tight glycemic control. The adequate delivery of non-protein calories was rigorously maintained in randomized controlled trials of surgical and medical ICU patients \[[@B6]-[@B8]\], and a recent single center study of SAH patients found that a bolus delivery of enteral nutrition significantly impacted brain glucose levels \[[@B9]\].

We sought to understand the impact enteral nutrition has upon the relationship between serum and brain interstitial glucose levels in a cohort of subarachnoid hemorrhage patients treated with institutional protocol targeting serum glucose levels between 5.5 to 7.8 mmol/l. We hypothesized that higher non-protein caloric delivery would result in higher interstitial brain glucose levels and reduce the incidence of brain metabolic crisis.

Materials and methods
=====================

Patient selection and data collection
-------------------------------------

Between June 2006 and August 2010 data were collected from 50 consecutive aneurysmal subarachnoid hemorrhage (SAH) patients admitted to the neurological ICU at Columbia University Medical Center, who underwent cerebral metabolism monitoring as part of their clinical care. All patients were enrolled in the Columbia University SAH Outcomes Project. This observational study was approved by the Columbia University Medical Center Institutional Review Board, and in all cases written informed consent was obtained from the patient or a surrogate. Details regarding data collection have been described previously \[[@B10]\]. The diagnosis of SAH was established on the basis of an admission CT scan or by presence of xanthochromia in the cerebrospinal fluid. Patients with secondary SAH related to trauma, rupture of an cerebral arteriovenous malformation (AVM), or other causes; age \< 18 years; or admission \> 14 days after SAH onset were excluded from the study.

Clinical and radiographic variables
-----------------------------------

The calendar day of the index bleeding event was designated SAH Day 0. We recorded baseline demographic data, location and size of the aneurysm, angiographic and transcranial Doppler ultrasonography (TCD) findings, and mode of aneurysm treatment (clipping versus coiling). Neurological status on admission was assessed with the Hunt-Hess scale \[[@B11]\], and the Glasgow Coma Scale (GCS; \[[@B12]\]). We also assessed the Acute Physiology and Chronic Health Evaluation II (APACHE II) scale \[[@B13]\] and calculated a physiological sub-score by subtracting the GCS score, age and chronic health elements from the total score \[[@B14]\]. Admission and follow-up CT scans were independently evaluated by a study neurointensivist for the amount and location of subarachnoid blood (SAH sum score, scaled 0 = no blood, 30 = all cisterns and fissures completely filled) \[[@B15]\], intraventricular blood (IVH sum score, scaled 0 = no blood, 12 = all ventricles completely filled) \[[@B16]\], the presence and degree of hydrocephalus \[[@B17]\], the presence of cerebral edema \[[@B18]\], and cerebral infarction.

Clinical management
-------------------

Clinical management conformed to guidelines set forth by the American Heart Association \[[@B19]\]. External ventricular drainage (EVD) was placed in all patients with symptomatic hydrocephalus or intraventricular hemorrhage with a reduced level of consciousness. All patients were followed with daily or every-other-day TCD, received oral nimodipine and intravenous hydration with 0.9% saline and 250 ml of 5% albumin solution to maintain a central venous pressure \> 5 cm H~2~O. Clinical deterioration from delayed cerebral ischemia (DCI) was treated with hypertensive hypervolemic therapy (HHT) to maintain systolic blood pressure (SBP) between 160 and 220 mm Hg, as required to reverse the neurological deficit. Comatose patients were mechanically ventilated and treated with propofol, fentanyl or dexmedetomidine to facilitate ventilator synchrony, with interruptions in sedation for clinical assessments at least twice daily. Computed tomography (CT) was performed serially when clinically needed. All patients with clinical deterioration underwent CT or magnetic resonance imaging (MRI) scanning to identify causes of deterioration other than vasospasm whenever clinically feasible. When clinical evidence of DCI persisted for more than two hours despite HHT, cerebral angiography was used to identify vasospasm and balloon angioplasty or intra-arterial administration of verapamil was performed whenever feasible.

Nutritional management
----------------------

Nutrition support was begun within 24 hours after aneurysmal repair. Enteral nutrition was the preferred route and was provided via a naso-duodenal tube starting within the first 24 hours of admission. All nutritional formulas were started at 50% of goal and were titrated by 25% every four hours until targeted caloric intake was achieved. Feeds were held for two hours if 100 cc of residual feeds were noted in the FARRELL^®^valve bag (Corpak MedSystems, Inc., Buffalo Grove, IL, USA), and resumed once the FARRELL^®^emptied. The target goal was 25 calories/kg/day of ideal body weight. No parenteral nutrition was given \[[@B20]\]. The type of enteral formula used was determined by the clinical nutritionist. All nutrition data were adjusted for actual body weight.

Serum glucose management
------------------------

Serum glucose was measured with the Sure Step Flexx system (Lifescan, Milpitas, CA, USA) and the target range was between 5.5 and 7.8 mmol/l (100 to 140 mg/dL) as part of an institutionally approved tight serum glucose control protocol using intravenous insulin infusion (Humulin, Novo Nordisk, Princeton, NJ, USA) \[[@B7]\].

Cerebral metabolism
-------------------

A CMA 70 microdialysis catheter with 10 mm membrane length (CMA Microdialysis^®^, Stockholm, Sweden) was inserted at the bedside through the same triple-lumen bolt as intracranial pressure (ICP) and brain tissue oxygen tension (P~bt~O~2~). Immediately after the procedure, a brain CT scan was performed in each patient to confirm the proper location of the microdialysis catheter in the normal appearing white matter. The CMA 106 microdialysis perfusion pump (CMA Microdialysis^®^) was used to perfuse the interior of the catheter with sterile artificial cerebrospinal fluid (Na^+^148 mmol/L, Ca^2+^1.2 mmol/L, Mg^2+^0.9 mmol/L, K^+^2.7 mmol/L, Cl^-^155 mmol/L) at a rate of 0.3 μl/minute. Samples were collected in microvials approximately every 60 minutes and immediately analyzed at the bedside for glucose, lactate and pyruvate with the CMA 600 analyzer (CMA Microdialysis^®^). At least one hour passed after the insertion of the probe and the start of the sampling to allow for normalization of changes due to probe insertion. The analyzer was automatically calibrated on initiation and every six hours using standard calibration solutions from the manufacturer. Quality controls at three different concentrations for each marker were performed daily.

Statistical analysis
--------------------

Caloric intake was quantified for enteral nutrition, dextrose infusions and propofol infusions. The volume (mL) of enteral nutrition delivered each hour was recorded and multiplied by the appropriate factor provided for each specific formulation. Hourly volumes (mL) of dextrose were converted into grams of dextrose and multiplied by 3.4 calories/gram dextrose. Propofol volumes (mL) were converted to calories by a factor of 1.1 calories/mL. Metabolic crisis was defined as a lactate/pyruvate ratio greater than 40 \[[@B5]\]. Comparisons of pooled data were carried out using a generalized linear model (GLM) using a normal distribution and identity link function and were extended by generalized estimating equations (GEE) using the autoregressive process (AR-1) \[[@B21]\] to handle repeated observations within subject. Data were transformed to meet assumptions of normality or converted into ordinal factors based on median or quartile values. Brain glucose was transformed using a square root transformation (bGlu_sqrt) whereas a Log transformation was applied to the lactate/pyruvate ratio (LPR_log). A Cook\'s distance was calculated in a linear analysis of bGlu_sqrt and LPR_log to identify outliers and a filter was applied using a cutoff of greater than 4/N \[[@B22]\] to remove the remaining data points that would distort linear analysis. SPSS 18 software^®^(IBM SPSS Inc., Chicago, IL, USA) was used for data analysis. A *P-*value \< 0.05 was considered statistically significant.

Results
=======

Baseline characteristics and nutrition
--------------------------------------

Fifty aneurysmal SAH patients met study criteria and were monitored for a total of 5,445 hours (108 +/- 73 hours/patient) between June 2006 and August 2010. The median Hunt &Hess Score on admission was 4 (IQR: 3, 5) and mean APACHE II score was 22 +/- 8 (Table [1](#T1){ref-type="table"}). Neuromonitoring began within four days after SAH in all but four patients (median = 2 days, IQR = 1 to 3.5 days). Enteral nutrition started on SAH bleed Day 4 +/- 2. The daily mean non-protein caloric intake was 14.8 ± 10.7 cal/kg and daily nitrogen intake was 0.087 ± 0.085 g/kg. The daily mean caloric intake from enteral tube feeds during the study period was 10.63 +/- 6.9 calories/kg/day, from dextrose 0.85 +/- 1.4 calories/kg/day, and from propofol 2.27 +/- 2.26 calories/kg/day totaling overall 13.77 +/- 6.95 calories/kg/day (Table [2](#T2){ref-type="table"}). Patients had a mean serum glucose of 7.9 +/- 1 mmol/l, brain glucose of 1.21 +/- 0.60 mmol/l, and LPR of 37 +/- 14. Higher insulin administration (IU) was associated with higher caloric intake from enteral tube feeds (Wald = 9.49, *P*= 0.009).

###### 

Baseline characteristics of subarachnoid hemorrhage patients (*N*= 50)

  Characteristic               **Value**^**1**^
  ---------------------------- ------------------
  Age, years                   51.2 (14.7)
  Women                        32 (64%)
  Ethnicity                    
   White, non-Hispanic         18 (36%)
   White, Hispanic             19 (38%)
   Black                       8 (16%)
   Asian                       5 (10%)
  Past medical history         
   Diabetes mellitus           5 (10%)
   Hypertension                17 (34%)
   Liver Disease               2 (4%)
   Kidney Disease              0 (0%)
  Body Mass Index, *kg/m^2^*   26 (5)
  APACHE II score^2^           22 (8)
  Glasgow Coma Scale           6 (5)
  Aneurysm size, mm^3^         7.7 (3.8)
  Aneurysm clipping            26 (52%)
  Admission Hunt Hess Grade    
   2                           3 (6%)
   3                           7 (14%)
   4                           15 (30%)
   5                           25 (50%)
  Modified Fisher Score        
   0                           1 (2%)
   1                           4 (8%)
   2                           9 (18%)
   3                           14 (28%)
   4                           22 (44%)

^1^All continuous measures are shown as mean (SD), ordinal measures as median (IQR), and nominal measures as N(%). ^2^Acute Physiological and Chronic Health Evaluation Score. ^3^One patient had a dysplastic aneurysm that was not measured for diameter.

###### 

Nutrition

  Characteristic          Mean (SD)
  ----------------------- ------------------
  Enteral Nutrition       Calories/Kg/Hour
   Carbohydrates          0.224 (0.142)
   Protein                0.085 (0.056)
   Fat                    0.133 (0.099)
  Intravenous Infusions   
   Dextrose               0.035 (0.057)
   Propofol               0.095 (0.094)

Serum glucose
-------------

On univariate analysis, higher serum glucose levels were associated with higher brain glucose concentrations (Wald = 30.4, *P*\< 0.001), doses of insulin administration (IU/hr: Wald = 92.25, *P*\< 0.001), body mass index (Wald = 213.47, *P*\< 0.001), and lower body temperature (Wald = 4.1, *P*= 0.043). Combined calories received from carbohydrates and dextrose administration were significantly related to serum glucose concentrations (Wald = 27.631, *P*\< 0.001, Figure [1](#F1){ref-type="fig"}) but associations were not found for total calories from enteral feeding (Wald = 2.173, *P*= 0.337), dextrose administration (Wald = 1.434, *P*= 0.488), or propofol (Wald = 5.284, *P*= 0.071). Multifactorial analysis revealed that increased calories from enteral feeding (Wald = 6.07, *P*= 0.048), higher insulin doses (Wald = 108.2, *P*\< 0.001), and presence of brain metabolic crisis (LPR \> 40) (Wald = 4.4, *P*= 0.036) were significantly associated with higher serum glucose concentrations. Insulin administration modified the relationship between serum glucose and enteral calories (Wald = 9.96, *P*= 0.041) such that serum glucose concentrations increases were smaller in magnitude in the presence of insulin administration, but insulin did not impact the relationship between serum glucose and brain metabolic crisis (Wald = 3.48, *P*= 0.176) (Table [3](#T3){ref-type="table"}, Figure [2](#F2){ref-type="fig"}).

![**Calories and Systemic Glucose**. Range plot of positive relationship between serum glucose to caloric intake from carbohydrates and dextrose (Wald = 27.631, *P*\< 0.001). Serum glucose estimated marginal mean and 95% confidence interval is presented.](cc11160-1){#F1}

###### 

Serum glucose: multifactorial associations

  Characteristic                                     Estimate (95% Confidence Interval)   *P-*Value
  -------------------------------------------------- ------------------------------------ -----------
  Enteral feeds (cal/kg/hour)                                                             
   0 to 0.068                                        (Reference)                          
   0.069 to 0.697                                    0.115 (-0.065, 0.296)                0.21
   0.70 to 2.16                                      0.249(-0.021, 0.520)                 0.07
  Insulin administration (units)                                                          
   0                                                 (Reference)                          
   1 to 2                                            0.678 (0.412, 0.944)                 \< 0.001
   \> 2                                              1.526 (1.124, 1.927)                 \< 0.001
  Lactate/pyruvate ratio ≤ 40                        -0.472 (-0.912, -0.032)              0.036
  Enteral feeds \* Insulin administration                                                 
   0 to 0.068 Cal/kg/hour \* 0 units                 (Reference)                          
   0.069 to 0.697 Cal/kg/hour \* 1 to 2 units        -0.356 (-0.676, -0.036)              0.029
   0.069 to 0.697 Cal/kg/hour \* \> 2 units          -0.562 (-0.980, -0.144)              0.008
   0.70 to 2.16 Cal/kg/hour \* 1 to 2 units          -0.232 (-0.646, 0.182)               0.272
   0.70 to 2.16 Cal/kg/hour \* \> 2 units            -0.216 (-0.787, 0.355)               0.458
  Insulin Administration \* LPR ≤ 40                                                      
   Insulin Administration \> 2 units \* LPR ≤ 40     (Reference)                          
   Insulin Administration 1 to 2 units \* LPR ≤ 40   0.160 (-0.035, 0.594)                0.436
   Insulin Administration 0 units \* LPR ≤ 40        0.419 (-0.067, 0.904)                0.091

![**Calories and Brain Glucose**. Observed association between insulin and brain glucose is modified by presence of metabolic crisis at the probe location. Brain glucose estimated marginal mean and 95% confidence interval is presented.](cc11160-2){#F2}

Brain glucose
-------------

Univariate analysis revealed that higher brain glucose was related to higher insulin doses (Wald = 24.68, *P*\< 0.001) and body mass index (Wald = 97.98, *P*\< 0.001), while lower brain glucose levels were associated with metabolic crisis (LPR \> 40; Wald = 14.79, *P*\< 0.001). There was no association observed between brain glucose levels and calories received from enteral feeding (Wald = 0.947, *P*= 0.623), propofol (Wald = 3.153, *P*= 0.207), dextrose (Wald = 5.76, *P*= 0.056) or body temperature (Wald = 3.05, *P*= 0.08). Multifactorial analysis revealed that enteral feeding (Wald = 1.743, *P*= 0.418) was not related to brain glucose concentrations after accounting for the positive relationship of serum glucose concentrations (Wald = 67.41, *P*\< 0.001) and negative relationship of metabolic crisis (Wald = 4.61, *P*= 0.032) to brain glucose concentrations. In this model insulin administration (Wald = 3.15, *P*= 0.208) was not associated with brain glucose but was modified by the existence of metabolic crisis (Wald = 8.26, *P*= 0.016) such that in the presence of metabolic crisis, administration of greater than two units of insulin was associated with a relative reduction of brain glucose concentrations (Table [4](#T4){ref-type="table"}, Figure [2](#F2){ref-type="fig"}).

###### 

Brain glucose: multifactorial associations

  Characteristic                                     Estimate (95% confidence interval)   *P-*Value
  -------------------------------------------------- ------------------------------------ -----------
  Enteral feeds (cal/kg/hour)                                                             
   0 to 0.068                                        (Reference)                          
   0.069 to 0.697                                    0.012 (-0.007, 0.032)                0.680
   0.70 to 2.16                                      -0.006 (-0.036, 0.024)               0.213
  Insulin administration (units)                                                          
   0                                                 (Reference)                          
   1 to 2                                            0.018 (-0.014, 0.049)                0.275
   \> 2                                              0.039 (0.003, 0.076)                 0.036
  Serum glucose (mmol/L)                             0.036 (0.027, 0.045)                 0.000
  Lactate/pyruvate ratio ≤ 40                        0.089 (0.027, 0.152)                 0.032
  Insulin administration (units) \* LPR ≤ 40                                              
   Insulin administration \> 2 units \* LPR ≤ 40     (Reference)                          
   Insulin administration 1 to 2 units \* LPR ≤ 40   -0.048 (-0.091, -0.005)              0.005
   Insulin administration 0 units\* LPR ≤ 40         -0.059 (-0.122, 0.004)               0.062

Discussion
==========

In this study of 50 poor-grade SAH patients, we found that our insulin protocol maintained serum glucose levels ≤ 7.8 mmol/l and similar to previous observations that low serum glucose levels were associated with brain metabolic crisis. We were unable; however, to directly demonstrate our central hypothesis that higher non- protein caloric delivery results in higher interstitial brain glucose levels. In contrast, Kinoshita *et al.*\[[@B9]\] demonstrated increases in serum and brain glucose concentrations two hours after a 250-calorie bolus of ENSURE^®^(Abbott Laboratories, Inc., Columbus, Ohio, USA **{**). This discrepancy is likely due to a significantly lower caloric delivery in our patients (0.442 calories/kg/hour) in combination with our intravenous insulin protocol that is designed to maintain serum glucose levels within a range of 5.5 to 7.8 mmol/l. Kinosheta *et al.*provided bolus feeds that resulted in higher serum glucose levels (183.8 ± 26.2 mg/dL) that were actively controlled in our observational study. This is a limitation experimentally but does suggest that brain metabolism is not supported by enteral nutrition under normal clinical circumstances. Underfeeding is a common problem in critically ill patients and as we and others have shown, it is associated with higher rates of medical and infectious complications as well as poor long term outcome \[[@B23],[@B24]\].

As expected, we observed greater administration of insulin as serum glucose levels increased. However, we were surprised to observe a different relationship between brain glucose levels and insulin doses. In 2011, Zetterling *et al.*\[[@B25]\] reported that insulin administration lowered cerebral microdialysis brain glucose and pyruvate concentrations, often to low levels, despite plasma glucose remaining above 6 mmol/L. While cerebral metabolism monitoring is used to detect acute events, in practice severity of the initial brain injury is the primary determinate of observed metabolic status \[[@B26]\]. An LPR greater than 40 has been established in the literature to represent a state of brain metabolic crisis (for example, \[[@B27]\]). We speculated that perhaps the effect of insulin on brain glucose concentration is altered by the severity of injury of the tissue being monitored. We found that when metabolic status was not critical (LPR \< 40) that the brain glucose-insulin administration relationship was similar to the serum glucose-insulin administration relationship. In contrast, during metabolic crisis (LPR ≥ 40) a negative relationship was observed, such that higher insulin doses (\> 2 IU/hr) were associated with a lower brain glucose level. While our observational study design restricts our ability to infer causal relationships between insulin and brain glucose, our observations do appear congruent with the findings of Zetterling *et al.*

It is physiologically plausible that the effect of insulin on brain glucose metabolism may be altered by brain injury. Previous experimental and clinical studies have shown that insulin increases glucose transport across the blood-brain barrier \[[@B28]\], promotes glucose storage as glycogen in astrocytes \[[@B29]\], and stimulates protein and RNA and DNA synthase in the brain \[[@B30],[@B31]\]. High concentrations of endogenous insulin may enable brain cells to divert glucose metabolism to secondary pathways \[[@B32],[@B33]\] that may be important to neuronal repair, including fatty acid and amino acid production, and the pentose phosphate shunt pathway, which may be important to protect against oxidative damage \[[@B34]\].

It is conceivable that protocol-driven clinical administration of insulin to maintain serum glucose concentrations may provide a dangerous false signal to injured brain tissue that excess glucose is available and can be diverted from ATP production to secondary pathways for tissue repair functions. Vespa *et al.*, \[[@B4]\] conducted a dual microdialysis positron emission tomography (PET) scan study in traumatic brain injury patients demonstrating that even though intensive insulin therapy resulted in lower brain glucose concentrations, the global metabolic rate of glucose did not change and that this corresponded with signs of energy failure, including oxygen extraction increases to near-ischemia level and brain glutamate and lactate pyruvate ratio increases. Two other studies found significant insulin-related reductions in brain glucose concentrations but did not find evidence that this resulted in increased metabolic distress \[[@B25],[@B35]\]. However, in both studies the reported mean LPR was approximately 30. No study has looked at the relationship between brain glucose levels and insulin during cerebral metabolic distress (LPR \> 40). Glucose metabolism of healthy brain tissue is stable and relatively unaffected by normal alterations of cerebral perfusion in contrast to that of injured brain tissue, which is very sensitive to such changes \[[@B36]\].

It is currently unknown if providing additional nutritional support to brain injured patients in combination with insulin therapy may be important to support increased cerebral energy demands and brain tissue recovery. The current cohort of patients, on average, received approximately half the amount of calories recommended by the American College of Chest Physicians\' guidelines for critically ill patients (approximately 25 calories/kg/day) \[[@B20]\], but is consistent with reports of underfeeding of neurological critically ill patients elsewhere \[[@B37]\]. We speculate that the effect of insulin on brain glucose metabolism in the context of brain injury remains poorly understood and is in need of further study.

Our study has several limitations. The true impact of enteral nutrition on brain metabolism is difficult to determine due to the fact that serum glucose concentrations were actively controlled with insulin. Evaluating relatively small-to-moderate differences in calories received over time may also mask the effects of enteral nutrition on brain metabolism. Individual responses to increases in calories received via enteral nutrition and the impact of insulin infusions were not analyzed in this study. Although our findings are consistent with the few studies available in this area \[[@B4],[@B9],[@B25],[@B35],[@B38]\], a patient-specific analysis might lead to different conclusions. This study does not provide any data to clarify a mechanism for insulin-related reductions of brain glucose concentrations or suggest whether adequate caloric intake (for example, 25 calories/kg/day) might mitigate this effect. Prospective studies with controlled amounts of caloric delivery are required to adequately address these limitations.

Conclusions
===========

Our data suggest that receiving even modest, though typical \[[@B37]\], levels of nutritional support is an effective way to increase serum glucose concentrations in poor-grade SAH patients and, accordingly, results in increased insulin administration to maintain target serum glucose concentrations. Improved algorithms designed to avoid underfeeding will be necessary to fully understand the incidence, mechanism and impact of insulin-induced reductions in brain glucose concentrations.

Key messages
============

• Higher caloric intake from enteral nutrition was associated with higher serum glucose concentrations and the amount of insulin administered.

• Caloric intake from enteral nutrition was not related to brain glucose concentrations after accounting for serum glucose concentrations.

• In the presence of metabolic distress, higher doses of insulin were associated with lower brain glucose levels.

• Further study is needed to understand how nutritional support and insulin administration can be optimized to minimize secondary injury after subarachnoid hemorrhage.
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